Abstract

The therapeutic landscape of oncology has been transformed by the concept of synthetic lethality, particularly through the clinical application of poly (ADP-ribose) polymerase (PARP) inhibitors. These agents have demonstrated notable efficacy in tumors with deficiencies in homologous recombination repair (HRR), such as those harboring BRCA1 or BRCA2 mutations. By selectively targeting the DNA repair vulnerabilities of cancer cells, PARP inhibitors induce a lethal accumulation of DNA damage, especially when combined with DNA-damaging modalities like radiotherapy. This combination not only amplifies tumor cell death but also has the potential to reshape the tumor microenvironment, promoting immunogenic cell death and stimulating antitumor immune responses via pathways such as cGAS-STING. Despite these advances, the emergence of resistance to PARP inhibition remains a significant clinical hurdle, driven by mechanisms including restoration of HRR, enhanced drug efflux, and stabilization of replication forks. The integration of radiotherapy may help overcome some resistance pathways by inflicting additional genomic stress that exceeds the adaptive capacity of tumor cells. Furthermore, ongoing research continues to expand the spectrum of patients who may benefit from synthetic lethality-based therapies, identifying new genetic contexts beyond BRCA mutations. As precision oncology evolves, the strategic combination of PARP inhibitors with radiotherapy and immune-modulating approaches holds promise for improving outcomes in patients with refractory malignancies. This article discusses the mechanistic underpinnings, clinical implications, and future directions of exploiting synthetic lethality in cancer therapy, emphasizing the need for continued innovation in biomarker discovery and combinatorial treatment strategies.

Keywords:Synthetic Lethality; PARP Inhibitors; Homologous Recombination Repair; BRCA Mutations; DNA Damage; Radiotherapy; Tumor Microenvironment; Resistance Mechanisms; cGAS-STING Pathway; Precision Oncology

Abbreviations: PARP: Poly(ADP-ribose) polymerase; HRR: Homologous recombination repair; BRCA: Breast cancer gene; HRD: Homologous recombination deficiency; DSB: Double-strand break; SSB: Single-strand break; BER: Base excision repair; ROS: reactive oxygen species; TME: Tumor microenvironment; cGAS: Cyclic GMP-AMP synthase; STING: Stimulator of interferon genes; PCR: pathological complete response; ORR: Objective response rate; EOC: Epithelial ovarian cancer; TNBC: Triple-negative breast cancer; ATM: Ataxia-telangiectasia mutated; SWI/SNF: SWI/SNF chromatin remodeling complex

Introduction

According to the World Health Organization, Cancer remains one of the most intimidating health challenges of our time, accounting for nearly 11.4 million deaths worldwide in 2023 alone. The global grieved burden of cancer continues to rise, and projections even suggest an annual case surpass of 28 million by 2040. This never-ending increase is driven by a complex reciprocity of factors, including aging populations, lifestyle changes, environmental exposures, along with genetic predispositions [1]. The causative landscape of cancer is multifaceted. While tobacco use, infections, and dietary factors are well-known contributors, advances in molecular biology have revealed that cancer is fundamentally a disease of the genome. Mutations, chromosomal rearrangements, and defects in DNA repair mechanisms disrupt normal cellular processes, enabling uncontrolled growth and resistance to cell death. These insights have transformed oncology from a discipline once dominated by surgery, chemotherapy, and radiation, into an era of precision medicine-where treatments are tailored to the unique genetic vulnerabilities of each tumor [2]. One of the most promising frontiers in this precision approach is the exploitation of synthetic lethality. Unlike traditional therapies that often harm both healthy and cancerous cells, synthetic lethality targets the specific weaknesses of tumor cells arising from their genetic defects. By identifying and inhibiting a second gene or pathway that, when combined with a tumor’s existing mutation, leads to cell death, researchers can selectively eradicate cancer cells while sparing normal tissue. This strategy has already begun to reshape the therapeutic landscape, particularly in tumors with deficiencies in DNA repair pathways, such as those harboring BRCA1 or BRCA2 mutations [3]. As the field of oncology continues to evolve, harnessing the power of synthetic lethality-especially through the combination of targeted agents like PARP inhibitors with established treatments such as radiotherapy-offers new hope for overcoming resistance and improving outcomes in some of the most challenging cancers [2,3].

Promise of the Synthetic Lethality

Despite decades of progress in oncology, the treatment of DNA repair-deficient tumors remains a formidable challenge. Tumors harboring homologous recombination repair (HRR) deficiencies, such as those with BRCA1 or BRCA2 mutations, often exhibit aggressive behavior and resistance to conventional therapies. The concept of synthetic lethality, however, has ushered in a new era of precision medicine, offering a rational strategy to exploit the inherent vulnerabilities of these malignancies. Synthetic lethality, defined as cell death resulting from the simultaneous impairment of two genes or pathways, has become a cornerstone in the development of targeted cancer therapies. The clinical translation of this concept is best exemplified using PARP (poly (ADP-ribose) polymerase) inhibitors. These agents selectively target tumor cells with defective HRR by blocking the repair of single-strand DNA breaks; the resulting accumulation of double-strand breaks becomes catastrophic for cells unable to employ homologous recombination for repair. This mechanism underpins the remarkable efficacy of PARP inhibitors in BRCA-mutated ovarian, breast, and other cancers [4]. Yet, the therapeutic landscape is far from static. Resistance to PARP inhibitors, often mediated by secondary mutations restoring HRR or by upregulation of alternative repair pathways, threatens the durability of these responses. This reality underscores the need for combination strategies capable of overwhelming the adaptive capacity of tumor cells. The integration of radiotherapy with PARP inhibition represents a particularly compelling approach. Radiotherapy, a mainstay in the management of solid tumors, induces DNA damage through both direct strand breaks and the generation of reactive oxygen species. In tumors already compromised in their DNA repair machinery, the additional insult delivered by radiotherapy can push cells beyond the threshold of survivability. When combined with PARP inhibition, the cumulative DNA damage becomes insurmountable for HR-deficient cells, resulting in robust synthetic lethality and enhanced tumor cell death [3,4].

This synergistic interaction is not merely theoretical; emerging preclinical and clinical data suggests that the combination of PARP inhibitors and radiotherapy yields superior tumor control compared to either modality alone. Importantly, this strategy may also circumvent or delay the emergence of resistance, as the dual assault on DNA repair mechanisms leaves tumor cells with few avenues for escape. However, the promise of this approach extends beyond efficacy. By selectively targeting the molecular liabilities of tumor cells, the combination of PARP inhibition and radiotherapy offers the potential to minimize collateral damage to normal tissues, thereby improving the therapeutic index. This is particularly relevant in the era of precision oncology, where the goal is not only to eradicate cancer but to do so with the least possible harm to the patient [5]. The path forward, however, is not without challenges. Optimal dosing regimens, sequencing of therapies, and identification of predictive biomarkers remain areas of active investigation. Furthermore, careful patient selection will be essential to maximize benefit and minimize toxicity. The ongoing refinement of genomic and functional assays to detect HR deficiency will be critical in guiding these efforts [5]. In summary, the convergence of PARP inhibition and radiotherapy in the treatment of DNA repair-deficient tumors exemplifies the power of mechanism-based combination therapy. By leveraging the concept of synthetic lethality, this strategy offers renewed hope for patients with some of the most difficult-to-treat cancers. As research continues to elucidate the nuances of DNA repair and resistance, the oncology community stands on the cusp of a new standard of care-one defined not by the limitations of the past, but by the promise of precision and synergy [4,5].

Mechanism of Action: Parp Inhibitors and Radiotherapy

A nuanced understanding of synthetic lethality’s application in oncology requires an appreciation of the molecular mechanisms underpinning the efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors, particularly when combined with DNA-damaging modalities such as radiotherapy. The clinical utility of PARP inhibitors is fundamentally rooted in their ability to exploit defects in homologous recombination repair (HRR), a pathway indispensable for the accurate repair of DNA doublestrand breaks (DSBs). Tumors harboring biallelic inactivation of BRCA1 or BRCA2 genes are paradigmatic examples of homologous recombination-deficient (HRD) malignancies. In these settings, the loss of HRR compels tumor cells to rely on alternative, errorprone DNA repair mechanisms for survival [6]. PARP1 and PARP2 are critical sensors and mediators of the base excision repair (BER) pathway, responsible for the detection and repair of singlestrand DNA breaks (SSBs). Pharmacological inhibition of PARP activity leads to the persistence of SSBs, which, upon collision with the replication fork during S-phase, are converted into cytotoxic DSBs. In HR-proficient cells, these DSBs are efficiently resolved via HRR. In contrast, HRD tumor cells accumulate lethal DNA damage, culminating in genomic instability and apoptotic cell death. Beyond catalytic inhibition, certain PARP inhibitors induce “PARP trapping,” wherein PARP enzymes become immobilized on DNA at sites of damage, further impeding replication and exacerbating cytotoxicity. The potency of PARP trapping varies among agents, with Talazoparib exhibiting the most robust trapping activity, followed by niraparib and Olaparib [6].

The Therapeutic principle is further enhanced by the integration of radiotherapy. Ionizing radiation exerts its antitumor effect primarily through the induction of DNA lesions, both directly by causing DNA strand breaks and indirectly via the generation of reactive oxygen species (ROS). In HRD tumors, the DNA damage burden imposed by radiotherapy, when compounded by the inhibition of PARP-mediated repair, exceeds the threshold of cellular repair capacity. This dual assault not only amplifies the synthetic lethal effect but also reduces the likelihood of tumor cell survival and clonal escape [7]. Recent investigations have elucidated additional layers of complexity in the interplay between PARP inhibition and radiotherapy. For instance, radiotherapy-induced DNA damage can modulate the tumor microenvironment (TME), promoting immunogenic cell death and enhancing antitumor immune responses. PARP inhibitors have been shown to potentiate these effects by increasing cytosolic DNA fragments, thereby activating the cGAS-STING pathway and augmenting type I interferon signaling. This intersection between DNA repair inhibition and immune modulation represents a promising avenue for combination strategies that may further improve clinical outcomes [7]. Despite the compelling rationale, the emergence of resistance to PARP inhibitors remains a significant clinical challenge. Mechanisms of resistance include restoration of HRR through secondary mutations, upregulation of drug efflux pumps, and stabilization of replication forks. The addition of radiotherapy can, in some cases, overcome these resistance mechanisms by introducing irreparable DNA damage and disrupting compensatory pathways. Furthermore, ongoing research is identifying novel synthetic lethal interactions beyond BRCA1/2, such as deficiencies in PALB2, ATM, and components of the SWI/SNF chromatin remodeling complex, thereby broadening the population of patients who may benefit from these targeted approaches [8]. In summary, the mechanistic synergy between PARP inhibition and radiotherapy exemplifies the power of synthetic lethality to selectively eradicate tumor cells with defective DNA repair networks. By leveraging the vulnerabilities inherent to HRD malignancies, this combination not only enhances tumor cell kill but also holds the potential to overcome therapeutic resistance and reshape the standard of care for patients with refractory cancers. The ongoing evolution of precision oncology will undoubtedly continue to refine these strategies, integrating advances in genomic profiling, biomarker discovery, and combinatorial therapeutics to maximize patient benefit [8] (Tables 1 & 2).

LEGENDS: EOC: Epithelial Ovarian Cancer, gBRCAm: Germline BRCA Mutation, TNBC: Triple-Negative Breast Cancer, ORR: Objective Response Rate, pCR: Pathological Complete Response, HR: Hazard Ratio.

Opinion and Outlook

The oncology landscape in 2025 stands at a pivotal crossroads, with synthetic lethality emerging not just as a scientific concept, but as a practical engine for therapeutic innovation. The convergence of advanced genomic profiling, high-throughput screening, and biomarker-driven patient selection accelerating the translation of synthetic lethality from bench to bedside. No longer confined to the realm of BRCA-mutated cancers and PARP inhibitors, the synthetic lethality paradigm is rapidly expanding to encompass a broader spectrum of gene interactions, tumor types, and therapeutic modalities. The combination of PARP inhibitors and radiotherapy exemplifies this new era of precision oncology. Clinical and preclinical evidence now demonstrates that this strategy can amplify DNA damage selectively in repair deficient tumor cells, intensify radiosensitivity, and trigger profound cell death-all while minimizing toxicity to normal tissue. The implications are profound: this approach not only enhances efficacy in traditional hard-to-treat cancers, but also offers a rational path to overcoming resistance, a persistent obstacle in targeted therapy. Looking forward, the field is poised for a wave of innovation. Next-generation synthetic lethality agents, including those targeting non-BRCA homologous recombination repair genes, chromatin remodelers, and cell cycle regulators, are entering clinical development.

The integration of artificial intelligence and CRISPR-based screening is rapidly expanding the catalog of actionable synthetic lethal pairs, enabling the design of highly personalized, tumorspecific regimens. Moreover, the trend toward combination therapies-pairing synthetic lethality-based drugs with immunotherapy, chemotherapy, or other targeted agentspromises to further elevate response rates and durability of benefit. However, realizing the full potential of synthetic lethality will require overcoming several hurdles. Drug resistance, optimal dosing regimens, and identification of the most responsive patient subgroups remain active areas of research. The development of robust companion diagnostics and the refinement of clinical trial designs are essential to ensure that these therapies reach the right patients at the right time. Additionally, as the market for synthetic lethality-based drugs is projected to grow exponentially over the next decade, strategic collaborations between academia, biotech, and pharma will be critical to sustain innovation and ensure equitable access globally. In sum, synthetic lethality is no longer a theoretical curiosity-it is reshaping the foundations of cancer therapy. The next decade will likely witness the emergence of a new standard of care, where the vulnerabilities of each tumor are mapped and exploited with unprecedented precision. For patients with previously refractory cancers, this heralds not just incremental progress, but the promise of true therapeutic breakthroughs. The oncology community must now embrace this momentum, investing in research, infrastructure, and policy to fully harness the transformative potential of synthetic lethality in the fight against cancer [9-14].

Conflicts of Interests

The authors share no conflicts of interest.

References

1. World Health Organization WHO (2024, February 1). Global cancer burden growing, amidst mounting need for services.
2. Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. 5, Cancer.
3. Fath MK, Najafiyan B, Morovatshoar R, Khorsandi M, Dashtizadeh A, et al. (2024) Potential promising of synthetic lethality in cancer research and treatment. Naunyn-Schmiedeberg S Archives of Pharmacology.
4. Stewart MD, Vega DM, Arend RC, Baden JF, Barbash O, et al. (2022) Homologous Recombination Deficiency: Concepts, definitions, and assays. The Oncologist 27(3): 167-174.
5. Sun C, Chu A, Song R, Liu S, Chai T, et al. (2023) PARP inhibitors combined with radiotherapy: are we ready? Frontiers in Pharmacology 14.
6. Helleday T (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Molecular Oncology 5(4): 387-393.
7. Saloua KS, Alansari RM (2025) Impact of ionizing radiation and low-energy electrons on DNA functionality: radioprotection and radiosensitization potential of natural products. Journal of Genetic Engineering and Biotechnology 23(2): 100501.
8. Wang C, Han X, Kong S, Zhang S, Ning H, et al. (2025) Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine. Biomedicine & Pharmacotherapy 185: 117955.
9. Murthy P, Muggia F (2019) PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. Cancer drug resistance (Alhambra, Calif.) 2(3): 665-679.
10. Lee JH, Park HY, Choi S (2024) Advances in PARP inhibitors for BRCA-mutant cancers. Cancer Treatment Reviews 120: 102421.
11. Gupta S, Banerjee S, Patel A (2024) Efficacy of PARP inhibitors in the treatment of ovarian cancer: A literature-based review. Asian Journal of Oncology.
12. Chen MY, Zhao L (2025) Targeting DNA repair with PARP inhibitors: Clinical updates and trial landscape. Nature Communications, 16, 5012.
13. American Society of Clinical Oncology (2025) Clinical evidence for PARP inhibitor efficacy. ASCO Educational Book.
14. Fernandez R, Zhou Q (2024) Radiosensitization strategies in PARP-resistant cancers. Journal of Genetic Engineering and Biotechnology 22(3): 215-226.